跳至主要内容
临床试验/NL-OMON52323
NL-OMON52323已完成4 期

A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual Antiplatelet Therapy (DAPT). - BIOFLOW-DAPT study

BIOTRONIK AG0 个研究点目标入组 1 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
BIOTRONIK AG
入组人数
1

研究概览

简要总结

Trial is onging in other countries

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • •- An acceptable candidate for treatment with a Drug Eluting Stent (DES)
  • •- Considered at high bleeding risk
  • •- >= 18 years old

排除标准

  • •- previously experienced stent or scaffold thrombosis in any coronary vessel.
  • •- Revascularization of any target vessel within 9 months prior to the index
  • •procedure or previous PCI of any non-target vessel within 72 hours prior to or
  • •during the index procedure.
  • •- judged by physician as inappropriate for discontinuation from DAPT at 1 month
  • •following index procedure, due to another condition requiring chronic DAPT.

研究者

发起方
BIOTRONIK AG

相似试验

A Prospective, Randomized, Multi-center Study to... | 临床试验